LY-344,545 is a research drug developed by the pharmaceutical company Eli Lilly, which acts as an antagonist for the metabotropic glutamate receptor subtype mGluR<sub>5</sub>. It is an epimer of another metabotropic glutamate receptor antagonist, the mGluR<sub>2/3</sub>-selective LY-341,495.